Translational and Clinical Research (TACR)

点击翻译按钮获取中文摘要

PROJECT SUMMARY/ABSTRACT (TRANSLATIONAL AND CLINICAL RESEARCH) The Translational and Clinical Research (TACR) Program catalyzes collaborations along the laboratory- translational-clinical research continuum and across solid tumor disease sites in the University of Michigan (U- M) Rogel Cancer Center (Rogel). TACR represents a crucial bridging mechanism for the Rogel, linking its laboratory and population science based-research programs that generate innovative concepts, agents, and approaches that TACR translates to solid tumor patient-oriented research. The TACR Program is comprised of 79 members from 15 different departments and four different schools and colleges. In 2022, TACR Program members had a total of $20.8M in annual direct cancer-relevant funding, of which $7.5M (36%) was from NCI; the Program had a total of $10.2M (49%) in peer-reviewed funding. In addition, TACR members had $10.6 million in grants from non-peer and industry sponsors. Members have a total of 1457 publications, of which 30.1% are intra-programmatic and 34.8% are inter-programmatic collaborations. The TACR program has three Specific Aims: 1) Develop and apply state-of-the-art molecularly targeted approaches to cancer diagnosis and treatment; 2) Develop and test new predictive biomarker and disease-monitoring strategies across tumor types; and 3) Advance concepts emanating from Rogel Cancer Center scientific programs to impactful clinical trials.